LOTTE BIOLOGICS Begins ADC Production at New York Site Following Biotech Agreement

• LOTTE BIOLOGICS has signed a manufacturing agreement with an Asia-based biotech firm for a clinical-stage ADC candidate.

• This marks the operational launch of its $100 million ADC facility at the Syracuse Bio Campus in New York.

LOTTE BIOLOGICS has signed a manufacturing agreement with an Asia-based biotechnology company to produce a clinical-stage antibody-drug conjugate (ADC) candidate. The announcement, made on the 24th, marks the company’s first contract in this therapeutic area and the official launch of its ADC contract development and manufacturing (CDMO) services.

The deal initiates full-scale operations at LOTTE BIOLOGICS’ ADC manufacturing facility at the Syracuse Bio Campus in New York. The site, which has been under expansion since 2023, was developed with a reported investment of approximately USD $100 million. The facility is cGMP-compliant and designed to offer end-to-end services—from antibody preprocessing to automated aseptic filling of drug substances.

The Syracuse facility features a conjugation reactor with a capacity of up to 1,000 litres and is supported by in-house quality control testing and advanced characterisation services. It is also equipped with a single-use system to enable flexible manufacturing responses across various project requirements.

Commenting on the agreement, CEO James Park said, “With this contract as a starting point, we will ensure a stable supply of high-quality ADC therapeutics and solidify our position in the global market, not only as an antibody manufacturer, but also as a CDMO specialising in ADCs.”

The company has also signalled plans to expand its customer base and form new partnerships, aiming to offer one-stop solutions across ADC development and manufacturing. A ribbon-cutting ceremony was recently held at the Syracuse campus to commemorate the completion of the facility, attended by senior executives and employees.